China is mid-way through the pilot rollout of its Marketing Authorisation Holder (MAH) scheme in ten provinces and municipalities. This report takes a look at the progress of the scheme’s implementation across different pilot areas since the State Council (China’s cabinet) issued the Pilot Plan in June 2016, and examines how market dynamics are expected to evolve as a major reform of the country’s drug commercialisation process takes place as China trials and tests the scheme until November 2018.
- Where is MAH having an impact? Find out the different degrees of progress on implementation of the MAH mechanism in the ten pilot areas
- How will market dynamics evolve?
- How can companies improve their chances of successful drug launches?